Molecular aspects of vitamin d anticancer activity

Cancer Investigation

Volumn 30, Issue 8, 2012, Pages 604-614

  Picotto, Gabriela ^a   Liaudat, Ana C ^a   Bohl, Luciana ^a   Tolosa de Talamoni, Nori ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Calcitriol; Cancer; Molecular mechanisms; Vitamin D

Indexed keywords

7 DEHYDROCHOLESTEROL; CALCIFEDIOL; CALCITRIOL; CELL ADHESION MOLECULE; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PREVENTION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; GENETIC POLYMORPHISM; GENOMICS; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VITAMIN METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CALCITRIOL; CALCIUM SIGNALING; CELL ADHESION MOLECULES; CELL CYCLE; CELL DIFFERENTIATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84866847896     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.721039     Document Type: Article

References (82)

1. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, KoskenvuoM, Pukkala E, SkyttheA, Hemminki K. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl JMed 2000;343:78-85.
2. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Op 2008;24:139-149.
3. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prevent Med 1990;19:612-622.
4. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007;103:708-711.
5. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alph-25-dihydroxyvitamin D2 (paracalcitol) in advance, androgen-insensitive prostate cancer. Clin Cancer Res 2005;11:8680-8685.
6. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;74:494-500.
7. King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N. The vitamin D/CYP24A1 story in cancer. Anticancer AgentsMed Chem 2010;10:213-224.
8. Demay MB. Mechanism of vitamin D receptor action. Ann NY Acad Sci 2006;1068:204-213.
9. Cui M, Klopo A, Jiang Y, Fleet JC. The effect of differentiation on 1, 25 dihydroxyvitamin D-mediated gene expression in the enterocyte-like cell line, Caco-2. J Cell Physiol 2009;218: 113-121.
10. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Rev 2007;7:684-700.
11. MizwickiMT, Norman AW.The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal 2009;2:re4.
12. Ordóñez-Morán P, Muñoz A. Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 2009;8: 1675-1680.
13. Costa JL, Eijk P, van de Wiel MA, ten Berge D, Schmitt F, Narvaez CJ, Welsh J, Ylstra B. Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics 2009;10:499-510.
14. Koren R, Wacksberg S, Weitsman GE, Ravid A. Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity while inhibiting caspase activation. J Steroid Biochem Mol Biol 2006;101:151-160.
15. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. The antiproliferative effects of 1-alpha-25(OH)2D3 on breast and cancer cells are associated with the induction of BRCA1 gene expression. Oncogene 2000;19:5091-5097.
16. Han SH, Jeon JH, Ju HR, JungU, KimKY, Yoo HS, Lee YH, Song KS, Hwang HM, Na YS, Yang Y, Lee KN, Choi I. VDUP1 upregulated by TGF-beta I and 1, 25-dihydroxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003;22:4035-4046.
17. Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res 2006;26:2543-2549.
18. Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, TatsumiH, Imai K, Shinomura Y, Tokino T. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 2006;66:4574-4583.
19. Marcinkowska E, Gocek E. Heat shock protein 90 interacts with vitamin D receptor in human leukemia cells. J Steroid Biochem Mol Biol 2010;121:114-116.
20. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010;17:273-285.
21. Brosseau CM, Pirianov G, Colston KW. Involvement of stress activated protein kinases (JNK and p38) in 1, 25 dihydroxyvitamin D3-induced breast cell death. Steroids 2010;75:1082-1088.
22. McGuire TF, Trump DL, Johnson CS. Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells: selective induction of caspase-dependent MEK cleavage and upregulation of MEKKK-1. J Biol Chem 2001;279:53213-53221.
23. Vanoirbeek E, Krishnan A, EelenG, Verlinden L, Bouillon R, Feldman D, Verstuyf A. The anti-cancer and anti-inflammatory actions of 1, 25(OH)2D3. Best Practice Res Clin Endocrinol Metab 2011;25:593-604.
24. Chen A, Davis BH, Bissonette M, Scaglione-Sewell B, Brasitus TA. 1, 25-Dihydroxyvitamin D3 stimulates activator protein 1-dependent Caco-2 cell differentiation. J Biol Chem 1999;274:35505-35513.
25. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE. 1alpha, 25-dihydroxyvitamin D3-induced myeloid cell differentiation is regulated by a vitamin D receptorphosphatidylinositol 3-kinase signaling complex. J Exp Med 1999;190:1583-1594.
26. Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2765-2772.
27. Pan L, Matloob AF, Du J, Pan H, Dong Z, Zhao J, Feng Y, Zhong Y, Huang B, Lu J. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation. FEBS J 2010;277:989-999.
28. Proietti S, Cucina A, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2010;50: 150-158.
29. Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. 1, 25-dihydroxyvitamin D3 and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate 2010;70:1658-1671.
30. Choi WS, Lee E, Lim J, Oh YJ. Calbindin-D28K prevents drug-induced dopaminergic neuronal death by inhibiting caspase and calpain activity. Biochem Biophys Res Commun 2008;371:127-131.
31. Tang JY, XiaoTZ, OdaY, ChangKS, Shpall E, WuA, SoPL, Hebert J, Bikle D, Epstein EH Jr. Vitamin D3 inhibits hedgehog signaling and proliferation inmurine basal cell carcinomas. Cancer Prev Res 2011;4:744-751.
32. Berridge MJ, Bootman MD, Lipp P. Calcium: a life and death signal. Nature 1988;395:645-648.
33. Bolanz KA, Hediger MA, Landowski CP. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 2008;7:271-279.
34. Inoue J, Choi J, Yoshidomi T, Yashiro T, Sato R. Quercetin enhances VDR activity leading to stimulation of its target gene expression in Caco-2 cells. J Nutr Sci Vitaminol 2010;56:326-330.
35. Song Y, Peng X, Porta A, Takanaga H, Peng JB, Hediger MA, Fleet JC, Christakos S. Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are different regulated by 1, 25 dihydroxyvitamin D3 in the intestine and kidney of mice. Endocrinology 2003;144:3885-3994.
36. Van Cromphaut SJ, Rummens K, Stockmans I, Van Herck E, Dijcks FA, Ederveen AG, Carmeliet P, Verhaeghe J, Bouillon R, Carmeliet G. Intestinal calciumtransporter genes are regulated by estrogens and the reproductive cycle through vitamin D receptorindependent mechanisms. J Bone Min Res 2003;18:1725-1736.
37. Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation viaCa2+/NFATdependent pathways. Oncogen 2007;26:7380-7385.
38. Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 1999;59:4848-4856.
39. Giacomello M, Drago I, Pizzo P, Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007;14:1267-1274.
40. Sareen D, Darjatmoko SR, Albert DM, Polans AS. Mitochondria, calcium and calpain are keymediators of resveratrol-induced apoptosis in breast cancer. Mol Pharmacol 2007;72:1466-1475.
41. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, JäätteläM. Calcium and calpain as keymediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem 2002;277:30738-30745.
42. Carafoli E, Molinari M.Calpain: a protease in search of a function? Biochem Biophys Res Commun 1998;247:193-203.
43. Gil-Parrado S, Fernandez-Montalvan A, Assfalg-Macnleidt I, Popp O, Bestvater F, Holloschi A, Knoch TA, Auerswald EA, Welsh K, Reed JC, Fritz H, Fuentes-Prior P, Spiess E, Salvesen GS, Machleidt W. Ionomycin-activated calpain triggers apoptosis: a probable role for Bcl-2 family members. J Biol Chem 2002;277:27217-27226.
44. Sergeev IN. Calcium as a mediator of 1, 25-dihydroxyvitamin D3-induced apoptosis. J Steroid Biochem Mol Biol 2004;89-90:419-425.
45. Sergeev IN. Calcium signaling in cancer and vitamin D. J Steroid Biochem Mol Biol 2005;97:145-151.
46. Hoyer-Hansen M, Bastholm L, Mathiasen IS, Elling F, Jää ttelä M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and beclin 1-mediated autophagic cell death. Cell Death Differ 2005;12:1297-1309.
47. Hoyer-HansenM, Schultz Nordbrandt SP, Jäätellä M. Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol Med 2010;16:295-302.
48. Marchionatti AM, Picotto G, Narvaez C, Welsh J, Tolosa de Talamoni NG. Antiproliferative action of menadione and 1, 25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol 2009;113:227-232.
49. Bohl LP, Liaudat AC, Picotto G, et al. Buthionine sulfoximine and 1, 25-dihydroxyvitamin D induce apoptosis in breast cancer cells via induction of reactive oxygen species. Cancer Investigation (In press).
50. Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A. Vitamin D is prooxidant in breast cancer cells. Cancer Res 2001;51:1439-1444.
51. Finkel T. Signal transduction by mitochondrial oxidants. J Biol Chem 2012;287:4434-4440.
52. Palmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. J Cell Biol 2001;154:369-387.
53. Pendás-Franco N, Aguilera O, Pereira F, González-Sancho JM, Muñoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res 2008;28:2613-2623.
54. Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol 2010;121:338-342.
55. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010;70:5953-5962.
56. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009;69:967-975.
57. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha, 25-dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007;6:1433-1439.
58. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-1081.
59. Feet JC, Desmet M, Johnson R, Li Y. Vitamin D and Cancer: a review of molecular mechanisms. Biochem J 2012;441: 61-76.
60. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006;66:4516-4524.
61. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1alpha, 25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005;35: 215-224.
62. Hamid AR, Umbas R, Mochtar CA. Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Med Indones-Indones J Intern Med 2001;43:59-65.
63. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1, 25-dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998;160:5314-5319.
64. Canning MO, Grotenhuis K, deWit H, Ruwhof C, Drexhage HA. 1-alpha, 25-dihydroxyvitamin D3 hampers the maturation of fully active immature dendritic cells frommonocytes. Eur J Endocrinol 2001;145: 351-357.
65. Rukin NJ, Strange RC. What are the frequency, distribution and functional effects of vitamin D receptor polymorphisms as related to cancer risk? Nutr Rev 2007;65:96-101.
66. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009;29:3511-3536.
67. Davis CD, Milner JA. Nutrigenomics, vitamin D and cancer prevention. J Nutrigenet Nutrigenomics 2011;4:1-11.
68. Kriebitzsch C, Verlinden L, Eelen G, Tan BK, Van CampM, Bouillon R, Verstuyf A. The impact of 1, 25(OH)2D3 and its structural analogs on gene expression in cancer cells: a microarray approach. Anticancer Res 2009;29:3471-3484.
69. Ward Y, Kelly K. Gem protein signaling and regulation. Methods Enzymol 2006;407:468-483.
70. Turunen MM, Dunlop TW, Carlberg C, Väisänen S. Selective use of multiple vitamin D response elements underlies the 1, 25-dihydroxyvitamin D3-mediated negative regulation of the human CUP27B1 gene. Nucleic Acid Res 2007;35:2734-2747.
71. Fleet JC. What have genomic and proteomic approaches told us about vitamin D and cancer? Nutr Rev 2007;65:127-130.
72. Byrne B, Welsh J. Identification of novel mediators of vitamin D signaling and 1, 25(OH)2D3 resistance inmammary cells. J Steroid Biochem Mol Biol 2007;103:703-707.
73. Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer 2010;1:101-107.
74. Rashid SF, Mountford JC, Gombart AF, Campbell MJ. 1α, 25-dihydroxyvitamin D3 displays divergent growth effects in both normal and malignant cells. Steroids 2001;66:433-440.
75. Murillo G, Matusiak D, Benyia RV, Mehta RG. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol 2007;103:763-767.
76. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? J Epidemiol 1980;9:227-231.
77. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, and Willett WC. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-459.
78. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
79. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
80. Suitor CW, Meyers LD. Dietary Reference Intakes Research Synthesis: Workshop Summary. Washington, DC: National Academies Press, 2006.
81. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:2287-2288.
82. IARC. Vitamin D and Cancer: IARC Working Group Reports. Lyon: International Agency for Research on Cancer, 2008.